Combined therapy led to superior outcomes compared with monotherapy, with evidence of reduced hepatic injury and restored immunological homeostasis.<h4>Conclusions</h4>The IL-33/ST-2 signaling pathway contributes to the pathogenesis of hepatic fibrosis and immunological dysregulation in AE by influencing eosinophil function. This evidence concerns the gene IL33 and Hepatic fibrosis.